XML 45 R34.htm IDEA: XBRL DOCUMENT
v3.22.2

Segments of Business (Tables) | 3 Months Ended
--- | ---
Jun. 30, 2022
Segment Reporting [Abstract] |
Schedule of financial information relating to reportable operating segments and reconciliations to the condensed consolidated totals | Financial information relating to the Company’s reportable operating segments and reconciliations to the condensed consolidated totals is as follows:
| Three Months Ended June 30, |  |  |  |
(In millions) | 2022 |  | 2021 |  |  |  |  |  |
Segment revenues (1) |  |  |  |  |  |  |  |  |
U.S. Pharmaceutical | $ | 56,947 |  |  | $ | 50,019 |  |  |  |  |  |  |
Prescription Technology Solutions | 1,066 |  |  | 881 |  |  |  |  |  |  |
Medical-Surgical Solutions | 2,592 |  |  | 2,528 |  |  |  |  |  |  |
International | 6,549 |  |  | 9,246 |  |  |  |  |  |  |
Total revenues | $ | 67,154 |  |  | $ | 62,674 |  |  |  |  |  |  |
Segment operating profit (loss) (2) |  |  |  |  |  |  |  |  |
U.S. Pharmaceutical (3) | $ | 696 |  |  | $ | 682 |  |  |  |  |  |  |
Prescription Technology Solutions | 144 |  |  | 104 |  |  |  |  |  |  |
Medical-Surgical Solutions (4) | 256 |  |  | 75 |  |  |  |  |  |  |
International (5) | (6) |  |  | 53 |  |  |  |  |  |  |
Subtotal | 1,090 |  |  | 914 |  |  |  |  |  |  |
Corporate expenses, net (6) | (39) |  |  | (303) |  |  |  |  |  |  |
Interest expense | (45) |  |  | (49) |  |  |  |  |  |  |
Income from continuing operations before income taxes | $ | 1,006 |  |  | $ | 562 |  |  |  |  |  |  |
(1)Revenues from services on a disaggregated basis represent less than 1% of the U.S. Pharmaceutical segment’s total revenues, less than 35% of the RxTS segment’s total revenues, less than 1% of the Medical-Surgical Solutions segment’s total revenues, and less than 8% of the International segment’s total revenues. The International segment reflects foreign revenues. Revenues for the remaining three reportable segments are derived in the U.S. (2)Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income, net, for the Company’s reportable segments. (3)The Company’s U.S. Pharmaceutical segment’s operating profit for the three months ended June 30, 2022 and 2021 includes $13 million and $23 million, respectively, of credits related to the last-in, first-out (“LIFO”) method of accounting for inventories. (4)The Company’s Medical-Surgical Solutions segment’s operating profit for the three months ended June 30, 2021 includes $164 million of inventory charges on certain personal protective equipment and other related products. (5)The Company’s International segment’s operating loss for the three months ended June 30, 2022 includes charges of $94 million to remeasure assets and liabilities of the E.U. disposal group to fair value less costs to sell, as discussed in more detail in Financial Note 2, “Held for Sale.” (6)Corporate expenses, net includes the following: •gains of $106 million for the three months ended June 30, 2022 primarily related to the effect of accumulated other comprehensive loss components from the E.U. disposal group, as discussed in more detail in Financial Note 2, “Held for Sale;” •charges of $5 million and $74 million for the three months ended June 30, 2022 and 2021, respectively, related to the Company’s estimated liability for opioid-related claims, as discussed in more detail in Financial Note 12, “Commitments and Contingent Liabilities;” •charges of $19 million and $35 million for the three months ended June 30, 2022 and 2021, respectively, of opioid-related costs, primarily litigation expenses; and •restructuring charges of $62 million for the three months ended June 30, 2021 primarily due to the transition to a partial remote work model for certain employees.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration